Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal

By Aditya Bhagchandani Published on June 16, 2025, 10:48 IST
Lupin Limited announced on June 16 that it has entered into a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of Tiotropium Dry Powder Inhaler (18 mcg/capsule) in China. This inhaler is used in the treatment of chronic obstructive pulmonary disease (COPD).
As per the deal, Sino Universal will handle regulatory approvals and distribution in China, while Lupin will retain marketing authorization and manage manufacturing. This marks a strategic push for Lupin to expand its respiratory product portfolio in one of the world's fastest-growing pharmaceutical markets.
Fabrice Egros, President of Corporate Development at Lupin, said the partnership underscores Lupin's commitment to global respiratory care. Wang Li, President of SUP, praised the collaboration, emphasizing how it aligns with SUP's mission to bring international innovation to China.
This development is expected to enhance Lupin's global respiratory footprint, especially in a country witnessing a rising burden of COPD.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

10 hours ago

• Yahoo

Roth Capital Hikes Verona Pharma's (VRNA) Price Target to $116 On COPD Market Prospects

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating. The adjustment follows remarks by Dr Frank Sciurba, who discussed unmet chronic obstructive pulmonary disease needs. A close up of a researcher in a laboratory, examining a new biopharmaceutical drug used to treat resistant bacterial infections. The doctor shared positive insights on the company's product Ohtuvayre, highlighting its complementary role in newly approved biologics. According to Roth Capital, the enhanced understanding of Verona Pharma's Ohtuvayre's distinctive efficacy and risk profile is already sparking greater interest among investors. Consequently, the research firm raised its price target in response to the increased attention and appreciation of Verona Pharma's offering. The research firm remains bullish about the company's growth potential. Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. It focuses on developing treatments for chronic obstructive pulmonary disease (COPD). They are known for their product, ensifentrine, an investigational, inhaled, small molecule that acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), combining bronchodilator and anti-inflammatory properties. While we acknowledge the potential of VRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Sign in to access your portfolio

Business Upturn

a day ago

• Business Upturn

Patanjali Foods receives FSSAI prohibition order on Ruchi No 1 Vanaspati batch

By Aditya Bhagchandani Published on June 21, 2025, 17:36 IST Patanjali Foods Ltd. has disclosed a regulatory development involving one of its products, Ruchi No 1 Vanaspati. The company received an official email communication on June 20, 2025, from the Assistant Director of the FSSAI's Central Licensing Authority in Kolkata. The notice prohibits the sale of a specific batch—HAE03702A—of Ruchi No 1 Vanaspati, citing non-conformity with a prescribed norm under Section 3(1)(zz)(xii) of the Food Safety & Standards Act, 2006. The company clarified that the issue pertains only to this batch and emphasized that the total financial implication is limited to approximately Rs 2.27 lakh. Patanjali Foods stated that there will be no material impact on the company's financial or operational performance due to this order. As a response, the company is pursuing appropriate legal action and has initiated an appeal against the order. No penalties, other than the prohibition of sale for the identified batch, have been imposed so far. This update was shared with the stock exchanges under Regulation 30 of SEBI Listing Regulations. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Washington Post

a day ago

• Washington Post

People with COPD had more carbon in their lungs than smokers in study

The lung tissue of people with chronic obstructive pulmonary disease contains triple the sootlike particle buildup found in similar tissue in smokers' lungs, a recent analysis finds. The study found that COPD patients' alveolar macrophages — a type of lung cell that removes dust, particles and microorganisms from the lungs — contain more carbon than those of smokers. The carbon-containing alveolar macrophages in COPD patients' lungs were also larger than macrophages without visible carbon, the study found.